NZ Rheumatology Research Review Issue 44

In this issue:

  -  Shingles risk with DMARDs for RA
  -  Tapering and stopping treatment for RA in stable remission
  -  Discontinuing biologic DMARDs for RA in remission
  -  Influence of obesity/overweight on disease activity in axial SpA
  -  COVID-19 risk in RA
  -  Low-dose glucocorticoids: withdraw or continue in systemic lupus erythematosus?
  -  Rheumatic/musculoskeletal disease flares and reactogenicity after COVID vaccination
  -  TNF inhibitor monotherapy vs. with conventional synthetic DMARDs in PsA
  -  Pain catastrophising hinders RA DAS28-ESR remission when CRP is normal
  -  Rituximab in polymyalgia rheumatica

Please login below to download this issue (PDF)